Terbinafine hydrochloride- Blueberry TherapeuticsAlternative Names: BB-2603
Latest Information Update: 16 Jan 2017
At a glance
- Originator Blueberry Therapeutics
- Class Peptide aptamers
- Mechanism of Action Protein folding inhibitors; Protein-protein interaction inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Onychomycosis; Tinea pedis
Most Recent Events
- 29 Dec 2016 Phase-I/II clinical trials in Onychomycosis and Tinea pedis in Germany (Topical) (EudraCT2016-001242-25)